, Tracking Stock Market Picks
Enter Symbol:
Celgene Corporation (CELG) [hlAlert]

up 534.06 %

Celgene Corporation (CELG) rated Buy with price target $61 by Lazard Capital Mkts

Posted on: Thursday,  Apr 30, 2009  2:25 PM ET by Lazard Capital Mkts

Lazard Capital Mkts rated Buy Celgene Corporation (NASDAQ: CELG) on 04/30/2009. Previously Lazard Capital Mkts rated Buy Celgene Corporation (NASDAQ: CELG) on
04/01/2009., when the stock price was $19.41. Since then, Celgene Corporation has gained 534.06% as of 01/14/2016's recent price of $123.04.
If you would have followed the previous Lazard Capital Mkts's recommendation on CELG, you would have gained 534.06% of your investment in 2479 days.

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

Lazard Capital Markets’ research team is broadly recognized for its insight, thoroughness, and objectivity. Lazard Capital Markets’ goal is to help our clients make the best-informed decisions by providing timely, thoughtful analysis as well as access to company management teams and industry thought leaders. Lazard Capital Markets’ industry-focused analysts strive to identify emerging sector trends as well as bottom-up fundamental issues affecting their stocks under coverage. We add value by conducting extensive primary survey work, hosting proprietary events, cultivating industry contacts, and participating in relevant industry conferences.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/30/2009 2:25 PM Buy
21.00 30.50
as of 12/31/2009
1 Week down  -0.62 %
1 Month up  1.04 %
3 Months up  0.23 %
1 YTD up  33.40 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/1/2009 9:25 AM Buy
19.41 33.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy